Vaccine News and Research

Latest Vaccine News and Research

Viewpoints: Health law's latest day in court; Obama's "abdication" on Medicare; Blue Shield profits vs. premiums

Provisions of the federal Affordable Care Act, also known as ObamaCare, "may violate the constitution of Ayn Rand, but they do not violate the Constitution of the United States," acting solicitor general Neal Kumar Katyal told a three-judge panel of the 11th Circuit Court of Appeals Wednesday. Conversely, attorney Paul Clement, representing Georgia and 25 other states, framed the issue of mandated purchase of health insurance as an issue of liberty.

10 Jun 2011

New vaccines on the horizon

In a report published in The Lancet, researchers say there is the potential to develop 20 new or improved vaccines over the next decade. They emphasize that funding is crucial - but so is trust and confidence in vaccines. It is said that AIDS and malaria vaccines as the most important areas for research. Authors further suggest that neglected tropical diseases, such as leprosy, should also be investigated.

9 Jun 2011

The ‘decade of vaccines’ has the potential to save lives, many challenges ahead

Vaccinating children around the world against infectious diseases has saved the lives of millions over the past several decades. Now new opportunities exist to overcome remaining challenges—and save another 6.4 million lives over the current decade, according articles in the June 2011 edition of Health Affairs. The issue was produced under the journal’s grant from the Bill & Melinda Gates Foundation.

9 Jun 2011

New vaccine leads to dramatic fall in meningitis A cases

Burkina Faso, Mali, and Niger report the lowest number of confirmed meningitis A cases ever recorded during an epidemic season this year following the successful introduction of a new vaccine that could eliminate the primary cause of the deadly disease from Africa's meningitis belt, announced the Meningitis Vaccine Project (MVP) today, which spearheaded development of the vaccine.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

9 Jun 2011

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness of some vaccines, induced CD8, or killer, T cells to join antibodies in response to influenza infection.

9 Jun 2011

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Scientists at Rockefeller University and The Scripps Research Institute have developed the first genetically humanized mouse model for hepatitis C, an achievement that will enable researchers to test molecules that block entry of the hepatitis C virus into cells as well as potential vaccine candidates. The finding is reported in the June 9 issue of the journal Nature.

9 Jun 2011

Scientists, advocacy experts form new international Foundation for Vaccine Research

Fourteen leading scientists and advocacy experts in vaccines and infectious diseases have announced the formation of a new international Foundation to advance and accelerate vaccine research and development against infectious diseases.

9 Jun 2011

ACAAI issues updated guidelines for treating stinging insect hypersensitivity

Spring and summer bring bees, wasps, hornets and yellow jackets and, this year, updated advice for those who are allergic to these pesky stinging insects. More than half a million people go to emergency rooms and at least 50 die each year from insect stings.

9 Jun 2011

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation announced today that the FDA has accepted an Investigational New Drug (IND) application for APC-100 to treat prostate cancer (PCa).

9 Jun 2011

Drop in flu vaccination rates alarms health authorities

According to latest figures the number of young children vaccinated against the flu in WA this year has plummeted almost 80 per cent. This is concerning for health officials who believe that parents have been scared off by last year's spate of seizures after the jabs.

8 Jun 2011

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, presented Phase 2 efficacy results for NeuVax in combination with trastuzumab at the American Society of Clinical Oncology (ASCO) annual meeting.

8 Jun 2011

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a detailed analysis of the data from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) has unanimously recommended termination of the study.

8 Jun 2011

GSK, Crucell to test second-generation malaria vaccine

GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine "within the next couple of months," Reuters reports.

8 Jun 2011

GAVI appeals for $3.7B ahead of pledging conference despite lower vaccine prices

The GAVI Alliance has appealed to donors for $3.7 billion to be pledged during an upcoming conference despite announcements by several major pharmaceutical companies to lower the prices of their vaccines for childhood diseases, the Associated Press/Washington Post reports.

8 Jun 2011

Lethal malaria parasite has biochemical weakness

Every year, 10,000 pregnant women and up to 200,000 newborn babies are killed by the malaria parasite. Doctors all around the globe have for years been looking in vain for a medical protection, and now researchers from the University of Copenhagen have found the biochemically weakness of the lethal malaria parasite, and will now start developing a vaccine to combat pregnancy related malaria.

8 Jun 2011

Vaccine candidate produces immune response to antigen in all strains of influenza A

A universal influenza vaccine targeting a protein common to all strains of influenza A has safely produced an immune response in humans. If proven effective, the vaccine could eliminate the practice of creating a new flu vaccine annually to match predicted strains, with major implications for global health.

8 Jun 2011

International coalition launches common platform to end AIDS epidemic

An international coalition of scientists and activists today launched a common platform for ending the AIDS epidemic. Thirty years into the epidemic, as world leaders come together at the United Nations to recommit to a global AIDS response, the broad-based international coalition issued a statement calling for world leaders to support a rational, evidence-based approach to responding to AIDS.

8 Jun 2011

Vaccine News and Research

Latest Vaccine News and Research

Viewpoints: Health law's latest day in court; Obama's "abdication" on Medicare; Blue Shield profits vs. premiums

New vaccines on the horizon

The ‘decade of vaccines’ has the potential to save lives, many challenges ahead

New vaccine leads to dramatic fall in meningitis A cases

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Scientists, advocacy experts form new international Foundation for Vaccine Research

ACAAI issues updated guidelines for treating stinging insect hypersensitivity

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Drop in flu vaccination rates alarms health authorities

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

GSK, Crucell to test second-generation malaria vaccine

GAVI appeals for $3.7B ahead of pledging conference despite lower vaccine prices

Lethal malaria parasite has biochemical weakness

Vaccine candidate produces immune response to antigen in all strains of influenza A

International coalition launches common platform to end AIDS epidemic

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Vaccine News and Research

Latest Vaccine News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in